Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 9/20 | 0.74 |
| ▸ | SLC2A4 | P14672 | 3/20 | 0.74 |
| ▸ | SLC2A8 | Q9NY64 | 1/20 | 0.62 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25722411 | 0.93 | SLC2A1 (0.62) | SLC2A1SLC2A4SLC2A8NR1H3KDM4E | |
| SCHEMBL20338615 | 0.85 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8NR1H3 | |
| SCHEMBL20339794 | 0.83 | SLC2A1 (0.71) | SLC2A1SLC2A4SLC2A8ALDH1A1F10 | |
| SCHEMBL20340003 | 0.79 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8KDM4EALDH1A1 | |
| SCHEMBL20339979 | 0.77 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8 | |
| SCHEMBL21500126 | 0.77 | SLC2A1 (0.72) | SLC2A1SLC2A4SLC2A8 | |
| SCHEMBL21500123 | 0.77 | SLC2A4 (1.00) | SLC2A1SLC2A4SLC2A8 | |
| SCHEMBL20339799 | 0.71 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8 | |
| SCHEMBL3509361 | 0.70 | SIRT2 (0.51) | SIRT2PPARGPPARDPPARAFFAR1 | |
| SCHEMBL20339753 | 0.69 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| US-20210113552-A1 | METHODS FOR ENHANCING CELLULAR CLEARANCE OF PATHOLOGICAL MOLECULES VIA ACTIVATION OF THE CELLULAR PROTEIN YKT6 | NORTHWESTERN UNIVERSITY (US) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | HSPA5, GBA1, SNCA | SLC2A1 1812/4885SLC2A4 1765/4885SLC2A8 1398/4885 |
| US-20210113552-A1 | METHODS FOR ENHANCING CELLULAR CLEARANCE OF PATHOLOGICAL MOLECULES VIA ACTIVATION OF THE CELLULAR PROTEIN YKT6 | CLN6, GBA3, GBA1 | SLC2A1 1405/4885SLC2A4 1337/4885SLC2A8 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.